Fitusiran: A Novel siRNA Therapy for Treatment of Hemophilia A & Hemophilia B, with or without Inhibitors

Time: 9:40 am


  • Fitusiran is a novel siRNA therapy targeting antithrombin in the coagulation cascade to rebalance hemostasis in patients with haemophilia A and haemophilia B, with or without inhibitors
  • GalNAc mediated liver targeted delivery allows monthly subcutaneous administration
  • Fitusiran is under Phase 3 clinical development